ArticleInternational journal of nanomedicine2023
Formulation and Evaluation of PLGA Nanoparticulate-Based Microneedle System for Potential Treatment of Neurological Diseases.
Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Nanoparticles in Vascular Dementia: Advantages and Challenges.CNS neuroscience & therapeutics · 2026Review
- Nano-formulated curcumin uptake and biodistribution in the fetal growth restricted newborn piglet brain.Drug delivery and translational research · 2026Article
- Microneedle Strategies for Diabetic Wound Management: A Comprehensive Review of Materials, Mechanisms, and Therapeutic Outcomes.Materials today. Advances · 2026Article
- Polymeric Microneedles: Advancing Potential Through Innovative Manufacturing, Polymer Design, and Characterization Techniques.Current pharmaceutical design · 2026Review
- The application prospect of microneedles for sports injuries: a narrative review.Annals of medicine · 2025Review
- Microneedle-nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics.Discover nano · 2025Review
- Dissolvable Microneedles Embedded with Chitosan Nanoparticles for Transdermal Delivery of Pramipexole Dihydrochloride in Parkinson's Disease.ACS omega · 2025Article
- Microneedle-aided nanotherapeutics delivery and nanosensor intervention in advanced tissue regeneration.Journal of nanobiotechnology · 2025Review
- Designing Multifunctional Microneedles in Biomedical Engineering: Materials, Methods, and Applications.International journal of nanomedicine · 2025Review
- Therapeutic potential of natural polymer-based transdermal drug delivery system for musculoskeletal disorders.Biomaterials translational · 2025Article
- Machine Learning Assists in the Design and Application of Microneedles.Biomimetics (Basel, Switzerland) · 2024Review
- Investigating Laser Ablation Process Parameters for the Fabrication of Customized Microneedle Arrays for Therapeutic Applications.Pharmaceutics · 2024Article
- Research Progress of Extracellular Vesicles-Loaded Microneedle Technology.Pharmaceutics · 2024Review
- Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo.International journal of nanomedicine · 2024Article
- Nanosuspension-Loaded Dissolving Microneedle Patches for Enhanced Transdermal Delivery of a Highly Lipophilic Cannabidiol.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The tight structure of the blood-brain barrier severely limits the level of drug therapy for central nervous system disorders. In this study, a novel composite delivery system combining nanocarrier and microneedle technology was prepared to explore the possibility of transdermal delivery of drugs to work in the brain. Methods: Nanoparticle solutions containing paroxetine and rhodamine-B were prepared using PLGA as a carrier by the emulsification-solvent volatilization method. Then, they were mixed with hyaluronic acid and the PLGA nanoparticulate-based microneedle system (Rh-NPs-DMNs) was prepared by a multi-step decompression-free diffusion method. The particle size, zeta potential, and micromorphology of the nano solution were measured; the appearance, mechanical strength, dissolution properties, and puncture effect of the Rh-NPs-DMNs were evaluated; also, it was evaluated for in vivo live imaging properties and in vitro skin layer transport and distribution properties. Results: The mean particle size of Rh-NPs was 96.25 ± 2.26 nm; zeta potential of 15.89 ± 1.97 mV; PDI of 0.120 ± 0.079. Rh-NPs-DMNs had a high needle content of 96.11 ± 1.27% and a tip height of 651.23 ± 1.28 μm, with excellent mechanical properties (fracture force of 299.78 ± 1.74 N). H&E skin tissue staining showed that Rh-NPs-DMNs produced micron-sized mechanical pores approximately 550 μm deep immediately after drug administration, allowing for efficient circulation of the drug; and the results of in vivo imaging showed that Rh-B NPs DMNs had a faster transport rate than Rh-B DMNs, with strong fluorescent signals in both brain ( Conclusion: Nanoparticles can prolong blood circulation time and intracerebral retention time and have certain brain-targeting properties due to their excellent physical properties. The use of microneedle technology combined with nanocarriers provides new ideas for delivery systems for the treatment of central neurological diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.